explore -WSS

explore

author：focus 2025-10-01 21:33:39 - browse：76

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Adam's Take: Intra

WSS

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Pregnant women don't need prenatal multivitamins, study concludes

Diabetes management: Digital health tools fall short, study says

Fetal cell organoids grown from amniotic fluid, study finds

Erich Jarvis studies song birds to learn about human stuttering

Cancer, immunology, HIV research ensnared in fetal tissue politics

knowledge

explore

focus

Drug repurposing or repositioning? The language matters

What Kate Middleton's cancer revelation might teach the world

Dobbs anniversary: the lost opportunity of abortion as health care

Cancer, immunology, HIV research ensnared in fetal tissue politics

In Memoriam: Notable people who died in 2023

Cancer, immunology, HIV research ensnared in fetal tissue politics

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Supreme Court strikes down use of affirmative action

Pregnant women don't need prenatal multivitamins, study concludes

hotspot

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Biotech investment managers search for lucrative opportunities

The untold story of TV’s first prescription drug ad

Change Healthcare: What is it, why does its cyberattack matter?

Asbestos ban is immediate, but health effects will linger for decades

Harvard's David Sinclair gets blowback over aging

hotspot

leisure time

hotspot

entertainment